Brokerages Set Stemline Therapeutics Inc (STML) PT at $33.75

Shares of Stemline Therapeutics Inc (NASDAQ:STML) have been assigned an average rating of “Buy” from the eight ratings firms that are currently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have given a buy recommendation to the company. The average 1-year price target among analysts that have covered the stock in the last year is $33.75.

A number of equities analysts have issued reports on STML shares. Zacks Investment Research cut shares of Stemline Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday. HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Stemline Therapeutics in a research report on Friday, February 2nd. ValuEngine upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Finally, BidaskClub upgraded shares of Stemline Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, January 26th.

In related news, insider David Gionco sold 4,250 shares of the business’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $13.43, for a total transaction of $57,077.50. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Kenneth Hoberman sold 11,943 shares of the business’s stock in a transaction dated Friday, December 15th. The stock was sold at an average price of $14.18, for a total transaction of $169,351.74. The disclosure for this sale can be found here. Insiders sold 47,887 shares of company stock worth $681,287 in the last 90 days. Corporate insiders own 15.70% of the company’s stock.

Large investors have recently bought and sold shares of the stock. C WorldWide Group Holding A S bought a new stake in Stemline Therapeutics during the third quarter worth about $1,776,000. Northern Trust Corp boosted its stake in Stemline Therapeutics by 18.0% during the second quarter. Northern Trust Corp now owns 274,824 shares of the biopharmaceutical company’s stock worth $2,529,000 after acquiring an additional 41,898 shares in the last quarter. Dimensional Fund Advisors LP boosted its stake in Stemline Therapeutics by 74.9% during the second quarter. Dimensional Fund Advisors LP now owns 120,477 shares of the biopharmaceutical company’s stock worth $1,108,000 after acquiring an additional 51,578 shares in the last quarter. Lyon Street Capital LLC boosted its stake in Stemline Therapeutics by 331.1% during the third quarter. Lyon Street Capital LLC now owns 541,462 shares of the biopharmaceutical company’s stock worth $6,010,000 after acquiring an additional 415,867 shares in the last quarter. Finally, Cowen Inc. bought a new stake in Stemline Therapeutics during the third quarter worth about $420,000. 42.52% of the stock is currently owned by institutional investors and hedge funds.

Stemline Therapeutics (NASDAQ:STML) traded down $0.05 during trading on Wednesday, reaching $15.90. 201,500 shares of the company’s stock traded hands, compared to its average volume of 328,594. The company has a market capitalization of $460.65, a P/E ratio of -6.19 and a beta of -0.02. Stemline Therapeutics has a 1-year low of $6.35 and a 1-year high of $17.40.

ILLEGAL ACTIVITY WARNING: “Brokerages Set Stemline Therapeutics Inc (STML) PT at $33.75” was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this report on another publication, it was stolen and reposted in violation of US and international copyright & trademark laws. The original version of this report can be viewed at https://stocknewstimes.com/2018/02/19/brokerages-set-stemline-therapeutics-inc-stml-pt-at-33-75.html.

About Stemline Therapeutics

Stemline Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing oncology therapeutics. The Company is developing approximately three clinical stage product candidates, including SL-401, SL-701 and SL-801. SL-401 is a targeted therapy directed to the interleukin-3 receptor (IL-3R) (CD123), present on a range of hematologic cancers.

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply